ziftomenib
oral menin-MLL1 inhibitor Ph. I/II candidate in leukemia from HTS and SBDD Leukemia, Sep 23, 2022 Kura Oncology, San Diego, CA
Molecules of the Month - September 2022
oral menin-MLL1 inhibitor Ph. I/II candidate in leukemia from HTS and SBDD Leukemia, Sep 23, 2022 Kura Oncology, San Diego, CA
Molecules of the Month - September 2022